Dexcel Pharma Technologies Ltd. 13D and 13G filings for Protalix BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-06-15 09:19 am Sale | 2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% | -2,521,914 (-55.35%) | Filing |
| 2021-02-16 12:06 pm Purchase | 2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% | 1,267,940 (+38.56%) | Filing |
| 2020-03-25 4:16 pm Purchase | 2020-03-18 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 3,288,091 9.990% | 3,288,091 (New Position) | Filing |